04/07/2020
New York Tech Alerts
LAST UPDATED MARCH 24, 2020
Effective Monday, March 23, all suspended in-person classes will resume remotely through the end of the spring 2020 semester. Information and links to resources for students and faculty/staff can be found at nyit.edu/covid.
The New York City campus will be closed, beginning Wednesday, March 25, until further notice. Long Island Campus Access Policy updates can be found at nyit.edu/alerts.
LESS-
ABOUT/CONTACT
CONTRIBUTORS
NYIT MAGAZINE
PRESS ROOM
EVENTS
HOME
NEWS
THE BOX
TB VACCINE COULD BE A VALUABLE WEAPON IN COVID-19 FIGHT

NEWS
TB Vaccine Could Be a Valuable Weapon in COVID-19 Fight
MARCH 30, 2020
RELATED TOPICS
The tuberculosis (TB) vaccine, Bacillus Calmette-Guerin (BCG), could be a potential weapon in combatting the deadly coronavirus according to findings published by NYIT College of Osteopathic Medicine (NYITCOM) researchers, led by Gonzalo Otazu, Ph.D., assistant professor of biomedical sciences.
The United States currently leads the world in confirmed COVID-19 cases, followed by Italy, per the latest report from Johns Hopkins University’s Center for Systems Science and Engineering (CSSE). Now NYITCOM researchers propose that the severity of COVID-19 impact may be linked to varying national policies on BCG childhood vaccination.
“We found that countries without universal policies of BCG vaccination, such as Italy, the Netherlands, and the United States have been more severely affected compared to countries with universal and long-standing BCG policies,” the researchers state.
According to the study, made widely available by MedRXiv, a combination of reduced morbidity and mortality could make the BCG vaccination a game-changer in the fight against COVID-19. As one of the most widely used vaccines in the world, the BCG vaccine has existed for nearly a century and has been shown to be an effective tool in preventing meningitis and disseminated TB in children. The inoculation is also believed to offer broad-ranging protection against respiratory infections, which present similar symptoms to COVID-19. In fact, Australian researchers have just announced plans to fast track large-scale testing to see if the BCG vaccination can protect health workers from the coronavirus.
Otazu, who is also a researcher in the new Center for Biomedical Innovation, completed the study with the assistance of NYITCOM students Aaron Miller, Mac Josh Reandelar, Kimberly Fasciglione, and Violeta Roumenova, along with Center technician Yan Li. The team compared various nations’ BCG vaccination policies with their COVID-19 morbidity and mortality and found a significant positive correlation between the year when universal BCG vaccination policies were adopted and the country’s mortality rate. In other words, the earlier a policy was established, the more likely that a significant portion of the population, especially the elderly, would be protected.
For example Iran, which has a current universal BCG vaccination policy that only started in 1984, has an elevated mortality rate with 19.7 deaths per million inhabitants. In contrast, Japan, which started its universal BCG policy in 1947, has approximately 100 times fewer deaths per million people, with 0.28 deaths. Furthermore, Brazil started universal vaccination in 1920 and has an even lower mortality rate of 0.0573 deaths per million inhabitants.
So why do some nations vaccinate while others do not? As TB cases fell in the late 20th century, several higher-income countries in Europe dropped their universal BCG policies between 1963 and 2010. In the United States, the CDC currently recommends the BCG vaccine only for very select persons who meet specific criteria and in consultation with a TB expert.
Among the 180 countries with BCG data available today, 157 countries currently recommend universal BCG vaccination. The remaining 23 countries have either stopped BCG vaccination due to a reduction in TB incidence or have traditionally favored selective vaccination of “at-risk” groups.

By Kim Tucker Campo
More Features
APRIL 06, 2020
New York Tech Faculty Donate PPE to Local Hospitals
APRIL 06, 2020
2020 Big Give: A Big Thank You!
APRIL 06, 2020
Q&A: Staying Connected While Social Distancing
APRIL 03, 2020
New Degree Programs Meet COVID-19 Crisis Needs and Prepare Students to Reinvent the Future
ALL NEWS
News
Events
Academic Calendar
Athletics
Career Services
Jobs
Policies
Non-Discrimination Statement
Privacy Statement
Terms & Conditions
Libraries
MY NYIT
EMERGENCY INFO
+SCHOOLS & COLLEGES
LOCATIONS
Long Island, NY
New York, NY
Jonesboro, AR
Vancouver, Canada
Abu Dhabi, UAE
China
GET IN TOUCH
Contact Us
Directory
Plan Your Visit
Follow New York Tech
Donate
©2020 New York Institute of Technology
Coronavirus (COVID-19) Information | College of Osteopathic Medicine | NYIT Effective Monday, March 23, all suspended in-person classes will resume remotely through the end of the spring 2020 semester. Information and links to resources for students and faculty/staff can be found at nyit.edu/covid.
03/15/2017
03/15/2017
03/15/2017
03/15/2017
01/08/2016
01/08/2016
01/08/2016
01/08/2016
01/08/2016